STOCK TITAN
  1. Home
  2. News
  3. SLRX

Salarius Pharmaceuticals Inc - SLRX STOCK NEWS

Welcome to our dedicated news page for Salarius Pharmaceuticals (Ticker: SLRX), a resource for investors and traders seeking the latest updates and insights on Salarius Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Salarius Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Salarius Pharmaceuticals's position in the market.

News
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Salarius Pharmaceuticals, Inc. resumes patient enrollment in a clinical trial for Seclidemstat in combination with Azacitidine for hematologic cancers. The company implemented expense-reduction measures to extend cash runway. Financial results show a decrease in net loss for Q4 2023 compared to Q4 2022. Seclidemstat shows promising results in treating Ewing sarcoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.74%
Tags
earnings
-
News
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
Rhea-AI Summary
Salarius Pharmaceuticals, Inc. (SLRX) implements cost-saving measures to extend cash runway till the first half of 2025. The measures support additional data generation from ongoing clinical trials in hematologic cancers and Ewing sarcoma, showing promising response rates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.93%
Tags
clinical trial
-
News
Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders
Rhea-AI Summary
Salarius Pharmaceuticals, Inc. (SLRX) has expanded its IP portfolio with composition-of-matter protection until 2039 for novel molecular glues, adding to its existing 17 issued patents across six patent families. This expansion covers the composition of matter for novel molecular glue degraders and extends the protection of Salarius’ targeted protein degradation (TPD) pipeline. The company is also exploring strategic options to advance the development of the TPD portfolio with third parties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.3%
Tags
none
News
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment
Rhea-AI Summary
Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that an additional Ewing sarcoma patient achieved a partial response in the Phase 1/2 clinical trial, bringing the objective response rate among first-relapse Ewing patients to 60%. The company continues to support clinical programs while exploring strategic alternatives. The FDA has removed the partial clinical hold on the MD Anderson trial with seclidemstat in blood cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
clinical trial
-
News
Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
Rhea-AI Summary
Salarius Pharmaceuticals, Inc. participated in an FDA Type B End-of-Phase 2 (EOP2) meeting to receive guidance regarding the development program for seclidemstat to treat Ewing sarcoma. The meeting included new Ewing sarcoma clinical data from an ongoing investigation, showing promising results for first-relapse patients. The company is amending the current clinical trial protocol to reflect guidance agreed to with FDA during the EOP2 meeting. Additionally, Salarius is evaluating strategic options to advance the clinical development of seclidemstat with a third party.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.62%
Tags
none
-
News
Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update
Rhea-AI Summary
Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) reported FDA removal of partial clinical hold for Ewing sarcoma Phase 1/2 study with seclidemstat SP-3164. The company also announced plans to explore strategic alternatives and implement cost-savings measures due to financial constraints. Key financial highlights include $11.5 million cash as of June 30, 2023, net loss of $3.9 million for Q2 2023, and a reduction in workforce by over 50%. The company is conducting a comprehensive review of strategic alternatives focused on maximizing shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.95%
Tags
earnings
News
Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources
Rhea-AI Summary
Salarius Pharmaceuticals plans to explore strategic alternatives and implement cost-saving measures, including a reduction in workforce by over 50%. No assurance of completing a transaction or disclosing developments. Positive clinical data and FDA clearance for SP-3164 Phase 1 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.95%
Tags
none
-
News
Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients
Rhea-AI Summary
Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) announces FDA clearance for Phase 1 clinical trial with SP-3164 in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). The trial will assess safety, efficacy, and the utility of a gene signature to identify potential responders. Patient dosing expected to begin in 2H 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.41%
Tags
clinical trial
-
News
Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
none
News
Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
none
Stock SLRX logo
Salarius Pharmaceuticals Inc

Nasdaq:SLRX

SLRX Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

SLRX Stock Data

2.16M
3.59M
6.74%
6.09%
6.23%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Houston

About SLRX

salarius is an oncology based biotechnology company developing targeted treatments for patients who need them the most.